uploads///Analysts Ratings

Gilead Sciences on the Street: Analyst Recommendations in October

By

Oct. 17 2017, Updated 8:39 a.m. ET

Recent acquisition

In October 2017, Gilead Sciences (GILD) acquired Kite Pharma for ~$11.9 billion. Kite Pharma’s expertise in cell therapy is expected to help Gilead Sciences establish a strong pipeline of cell therapy for oncology. Kite Pharma’s pipeline and scientific expertise could help Gilead Sciences develop a strong foundation for the development of cell therapy for treatment of hematological cancers and solid tumors.

Kite Pharma’s Axi-cel is currently under review by the FDA (US Food and Drug Administration), which has provided a PDUFA (Prescription Drug User Fee Act) action date of November 2017.

Kite Pharma anticipates the European Commission’s approval for Axi-cel by 2018. The FDA has also designated Axi-cel as a breakthrough therapy for transformed follicular lymphoma, diffuse large B-cell, and primary mediastinal B-cell lymphoma.

Article continues below advertisement

Analyst recommendations

Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy,” 14 have recommended a “hold.” None has recommended any form of “sell” rating.

Around 50% of the analysts tracking Gilead Sciences in October 2017 recommended some form of a “buy.” On October 13, 2017, Gilead Sciences had a consensus target price of $84.35, which represents a ~3.8% return on investment over the next 12 months.

Notably, the iShares Nasdaq Biotechnology ETF (IBB) invests ~8.04% of its total portfolio holdings in Gilead Sciences.

Peer ratings

Of 26 analysts tracking Regeneron Pharmaceuticals (REGN) in October 2017, ~50% recommend a “buy.” On October 13, 2017, Regeneron had consensus target price of $497.96, which represents an 11.4% return on investment over the next 12 months.

Of the 13 analysts tracking Clovis Oncology (CLVS) in October 2017, ~69% recommend some form of “buy.” On October 13, 2017, CLVS had consensus target price of $93.73, which represents an ~11.3% return on investment over the next 12 months.

Of the ten analysts tracking Exelixis (EXEL) in October 2017, ~60% recommend some form of a “buy.” On October 13, 2017, EXEL had a consensus target price of $29.71, which represents a ~20.2% return on investment over the next 12 months.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.